Zentalis Pharmaceuticals Inc (ZNTL)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Zentalis Pharmaceuticals Inc chart...

About the Company

developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer

CEO

Kimberly Lynn Blackwell

Exchange

NASDAQ

Website

zentalis.com

$0M

Total Revenue

166

Employees

$1B

Market Capitalization

-3.37

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ZNTL News

Zentalis Pharmaceuticals Inc Ordinary Shares

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock

1mon ago, source: Zacks.com on MSN

Earnings Estimate Revisions for Zentalis Pharmaceuticals, Inc. This company is expected to earn -$4.49 per share for the fiscal year ending December 2023, which represents a year-over-year change ...

Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Price

28d ago, source: Yahoo Finance

The projected fair value for Zentalis Pharmaceuticals is US$ ... are going to estimate the intrinsic value of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by estimating the company's future cash ...

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

1mon ago, source: Business Insider

Corporate Updates Anticipated Upcoming Milestones Full Year 2023 Financial Results About Azenosertib Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and ...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26d ago, source: Business Insider

NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...

Zentalis Pharmaceuticals Inc Ordinary Shares ZNTL

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

27d ago, source: Stockhouse

NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

26d ago, source: ADVFN

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...